Lorraine L. Janeczko, MPH January 25, 2023 People with untreatable dystrophic epidermolysis bullosa (DEB) may soon have access to an investigational gene therapy delivered in a topical gel that is currently under review by the US Food and Drug Administration (FDA). In a phase 3 study of patients with DEB, “we found that repeated topical application of B-VEC [beremagene geperpavec], an...